[Efficacy and safety of recombinant tissue plasminogen activator in thrombolytic therapy of vena caval thromboembolism].
To explore the efficacy and safety of recombinant tissue plasminogen activator (rt-PA) in thrombolytic therapy of vena caval thromboembolism. Ninety patients diagnosed of vena caval thromboembolism by ultrasound or angiography of inferior vena cava were randomly assigned into 2 groups. rt-PA and parental anticoagulant were given to the patients in the treatment group while those in the control group received only parental anticoagulation. D-dimer, fibrinogen and fibrinogen degradation product were analyzed after 2-week treatment. All subjects were closely monitored for the occurrence of severe complications. The changes from baseline in the above laboratory parameters in the treatment group were significantly greater than those of the control group (P < 0.05). No severe complications occurred in either group. rt-PA is both safe and effective for the thrombolytic therapy of vena caval thromboembolism.